|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL11 |
Gene summary for RPL11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL11 | Gene ID | 6135 |
| Gene name | ribosomal protein L11 | |
| Gene Alias | DBA7 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0000027 | UniProtAcc | P62913 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6135 | RPL11 | CA_HPV_1 | Human | Cervix | CC | 4.23e-06 | -1.71e-01 | 0.0264 |
| 6135 | RPL11 | CA_HPV_2 | Human | Cervix | CC | 3.55e-20 | -2.45e-01 | 0.0391 |
| 6135 | RPL11 | CCI_1 | Human | Cervix | CC | 2.52e-76 | -2.06e+00 | 0.528 |
| 6135 | RPL11 | CCI_2 | Human | Cervix | CC | 1.16e-77 | -1.96e+00 | 0.5249 |
| 6135 | RPL11 | CCI_3 | Human | Cervix | CC | 4.16e-94 | -2.02e+00 | 0.516 |
| 6135 | RPL11 | CCII_1 | Human | Cervix | CC | 2.73e-96 | -2.17e+00 | 0.3249 |
| 6135 | RPL11 | Tumor | Human | Cervix | CC | 1.13e-62 | -3.31e-01 | 0.1241 |
| 6135 | RPL11 | sample1 | Human | Cervix | CC | 2.05e-16 | -3.06e-01 | 0.0959 |
| 6135 | RPL11 | sample3 | Human | Cervix | CC | 3.36e-93 | -4.19e-01 | 0.1387 |
| 6135 | RPL11 | H2 | Human | Cervix | HSIL_HPV | 1.37e-52 | -3.66e-01 | 0.0632 |
| 6135 | RPL11 | L1 | Human | Cervix | CC | 3.45e-07 | -2.15e-01 | 0.0802 |
| 6135 | RPL11 | T1 | Human | Cervix | CC | 5.81e-49 | -4.14e-01 | 0.0918 |
| 6135 | RPL11 | T2 | Human | Cervix | CC | 8.24e-03 | -1.57e-01 | 0.0709 |
| 6135 | RPL11 | T3 | Human | Cervix | CC | 5.25e-94 | -4.17e-01 | 0.1389 |
| 6135 | RPL11 | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.63e-119 | 2.51e+00 | 0.0155 |
| 6135 | RPL11 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.89e-66 | 2.67e+00 | -0.1808 |
| 6135 | RPL11 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.54e-29 | 2.58e+00 | 0.0216 |
| 6135 | RPL11 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.06e-65 | 2.70e+00 | -0.0811 |
| 6135 | RPL11 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.08e-45 | 1.80e+00 | -0.1088 |
| 6135 | RPL11 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.56e-103 | 2.93e+00 | -0.1954 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005109929 | Thyroid | goiters | positive regulation of binding | 17/497 | 173/18723 | 3.77e-06 | 1.77e-04 | 17 |
| GO:005109829 | Thyroid | goiters | regulation of binding | 26/497 | 363/18723 | 4.97e-06 | 2.29e-04 | 26 |
| GO:190225329 | Thyroid | goiters | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 7/497 | 29/18723 | 8.37e-06 | 3.54e-04 | 7 |
| GO:1904667210 | Thyroid | goiters | negative regulation of ubiquitin protein ligase activity | 5/497 | 12/18723 | 8.77e-06 | 3.67e-04 | 5 |
| GO:0031397210 | Thyroid | goiters | negative regulation of protein ubiquitination | 11/497 | 83/18723 | 1.19e-05 | 4.82e-04 | 11 |
| GO:0042176210 | Thyroid | goiters | regulation of protein catabolic process | 26/497 | 391/18723 | 1.84e-05 | 7.00e-04 | 26 |
| GO:1904666210 | Thyroid | goiters | regulation of ubiquitin protein ligase activity | 6/497 | 23/18723 | 2.33e-05 | 8.78e-04 | 6 |
| GO:0045861210 | Thyroid | goiters | negative regulation of proteolysis | 24/497 | 351/18723 | 2.46e-05 | 9.17e-04 | 24 |
| GO:1903321210 | Thyroid | goiters | negative regulation of protein modification by small protein conjugation or removal | 11/497 | 95/18723 | 4.32e-05 | 1.52e-03 | 11 |
| GO:003466014 | Thyroid | goiters | ncRNA metabolic process | 29/497 | 485/18723 | 4.41e-05 | 1.53e-03 | 29 |
| GO:2001233210 | Thyroid | goiters | regulation of apoptotic signaling pathway | 23/497 | 356/18723 | 8.60e-05 | 2.78e-03 | 23 |
| GO:1903050210 | Thyroid | goiters | regulation of proteolysis involved in cellular protein catabolic process | 17/497 | 221/18723 | 9.04e-05 | 2.90e-03 | 17 |
| GO:0051444210 | Thyroid | goiters | negative regulation of ubiquitin-protein transferase activity | 5/497 | 19/18723 | 1.10e-04 | 3.41e-03 | 5 |
| GO:200124426 | Thyroid | goiters | positive regulation of intrinsic apoptotic signaling pathway | 8/497 | 58/18723 | 1.39e-04 | 4.10e-03 | 8 |
| GO:190336327 | Thyroid | goiters | negative regulation of cellular protein catabolic process | 9/497 | 75/18723 | 1.61e-04 | 4.58e-03 | 9 |
| GO:0010498210 | Thyroid | goiters | proteasomal protein catabolic process | 27/497 | 490/18723 | 3.03e-04 | 7.94e-03 | 27 |
| GO:0051348210 | Thyroid | goiters | negative regulation of transferase activity | 18/497 | 268/18723 | 3.10e-04 | 8.09e-03 | 18 |
| GO:004217727 | Thyroid | goiters | negative regulation of protein catabolic process | 11/497 | 121/18723 | 3.81e-04 | 9.50e-03 | 11 |
| GO:0031330210 | Thyroid | goiters | negative regulation of cellular catabolic process | 17/497 | 262/18723 | 6.68e-04 | 1.55e-02 | 17 |
| GO:000660529 | Thyroid | goiters | protein targeting | 19/497 | 314/18723 | 7.74e-04 | 1.73e-02 | 19 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030104 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
| hsa030105 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL11 | deletion | Frame_Shift_Del | novel | c.516delG | p.Ile173SerfsTer21 | p.I173Sfs*21 | P62913 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| RPL11 | SNV | Missense_Mutation | c.424G>A | p.Ala142Thr | p.A142T | P62913 | protein_coding | tolerated(0.19) | benign(0.031) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RPL11 | SNV | Missense_Mutation | novel | c.496T>C | p.Phe166Leu | p.F166L | P62913 | protein_coding | tolerated(0.14) | benign(0.075) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RPL11 | SNV | Missense_Mutation | novel | c.386N>T | p.Asp129Val | p.D129V | P62913 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-F5-6812-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| RPL11 | SNV | Missense_Mutation | novel | c.515N>A | p.Gly172Glu | p.G172E | P62913 | protein_coding | deleterious(0) | possibly_damaging(0.764) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL11 | SNV | Missense_Mutation | novel | c.413N>A | p.Gly138Asp | p.G138D | P62913 | protein_coding | deleterious(0.03) | possibly_damaging(0.539) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL11 | SNV | Missense_Mutation | novel | c.365N>T | p.Ser122Ile | p.S122I | P62913 | protein_coding | deleterious(0.02) | benign(0.213) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| RPL11 | SNV | Missense_Mutation | rs770776620 | c.437N>A | p.Arg146His | p.R146H | P62913 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| RPL11 | SNV | Missense_Mutation | novel | c.47G>A | p.Arg16His | p.R16H | P62913 | protein_coding | tolerated(0.2) | benign(0.052) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| RPL11 | SNV | Missense_Mutation | novel | c.235N>A | p.Ala79Thr | p.A79T | P62913 | protein_coding | deleterious(0.01) | possibly_damaging(0.451) | TCGA-AX-A2H7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |